Allergan plc (AGN)
Stock Price Chart
Key Info
| Market Cap | 63.36B |
| Revenue (ttm) | 16.10B |
| Net Income (ttm) | -2.49B |
| Shares Out | 329.81M |
| EPS (ttm) | -7.57 |
| PE Ratio | n/a |
| Forward PE | 11.89 |
| Dividend | $2.96 |
| Dividend Yield | 1.53% |
Stock Quote
| Trading Day | May 8, 2020 |
| Last Price | $193.02 |
| Previous Close | $193.02 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 191.64 - 193.38 |
| Day's Volume | 0 |
| 52-Week Range | 114.27 - 202.22 |
More Stats
| Market Cap | 63.36B |
| Enterprise Value | 80.85B |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | Apr 15, 2020 |
| Shares Outstanding | 329.81M |
| Float | 329.60M |
| EPS (basic) | -7.6 |
| EPS (diluted) | -7.57 |
| FCF / Share | 17.50 |
| Dividend | $2.96 |
| Dividend Yield | 1.53% |
| Earnings Yield | n/a |
| FCF Yield | 9.09% |
| Payout Ratio | n/a |
| Shares Short | 15.01M |
| Short Ratio | 3.22 |
| Short % of Float | 4.56% |
| Beta | 1.20 |
| PE Ratio | n/a |
| Forward PE | 11.89 |
| P/FCF Ratio | 11.00 |
| PS Ratio | 3.94 |
| PB Ratio | 1.10 |
| Revenue | 16.10B |
| Operating Income | -3.44B |
| Net Income | -2.49B |
| Free Cash Flow | 5.76B |
| Net Cash | -17.49B |
| Net Cash / Share | -53.28 |
| Gross Margin | 84.83% |
| Operating Margin | -21.34% |
| Profit Margin | -15.40% |
| FCF Margin | 35.78% |
| ROA | 0.74% |
| ROE | -4.15% |
| ROIC | -13.90% |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16,089 | 15,787 | 15,941 | 14,571 | 12,688 | 4,677 | 2,603 | 5,915 | 4,584 | 3,567 |
| Revenue Growth | 1.91% | -0.96% | 9.4% | 14.84% | 171.32% | 79.69% | -56% | 29.02% | 28.53% | - |
| Gross Profit | 13,596 | 13,596 | 13,773 | 12,710 | 9,936 | 2,972 | 958 | 2,521 | 2,018 | 1,568 |
| Operating Income | -4,445 | -6,248 | -5,921 | -1,826 | -3,131 | -2,567 | -369 | 316 | 523 | 305 |
| Net Income | -5,271 | -5,096 | -4,126 | 14,973 | 3,915 | -1,631 | -750 | 97.30 | 261 | 184 |
| Shares Outstanding | 329 | 337 | 334 | 385 | 368 | 220 | 142 | 126 | 125 | 122 |
| Earnings Per Share | -16.02 | -15.26 | -13.19 | 38.18 | 10.01 | -7.42 | -5.27 | 0.76 | 2.06 | 1.48 |
| EPS Growth | - | - | - | 281.42% | - | - | - | -63.11% | 39.19% | - |
| Dividend Per Share | 2.96 | 2.88 | 2.80 | - | 0.10 | 0.20 | 0.10 | - | - | - |
| Dividend Growth | 2.78% | 2.86% | - | - | -50% | 100% | - | - | - | - |
| Operating Cash Flow | 7,239 | 5,640 | 6,079 | 1,446 | 4,606 | 2,243 | 1,214 | 666 | 632 | 571 |
| Capital Expenditures | -352 | -223 | -343 | -298 | -315 | -225 | -171 | -130 | -120 | -53.90 |
| Free Cash Flow | 6,887 | 5,417 | 5,736 | 1,148 | 4,291 | 2,018 | 1,043 | 536 | 512 | 517 |
| Cash & Equivalents | 5,915 | 1,907 | 6,449 | 13,226 | 1,105 | 251 | 332 | 328 | 224 | 294 |
| Total Debt | 23,220 | 23,798 | 30,075 | 32,769 | 42,530 | 15,531 | 9,052 | 6,433 | 1,033 | 1,016 |
| Net Cash / Debt | -17,305 | -21,890 | -23,626 | -19,543 | -41,425 | -15,280 | -8,721 | -6,105 | -809 | -722 |
| Assets | 94,699 | 101,788 | 118,342 | 128,986 | 135,583 | 52,758 | 22,726 | 14,115 | 6,698 | 5,687 |
| Liabilities | 36,503 | 36,657 | 44,505 | 52,786 | 58,994 | 24,423 | 13,189 | 10,258 | 3,136 | 2,404 |
| Book Value | 58,174 | 65,114 | 73,821 | 76,193 | 76,591 | 28,331 | 9,532 | 3,834 | 3,564 | 3,282 |
Company Profile
Company Details
| Full Name | Allergan plc |
| Country | Ireland |
| Employees | 17,400 |
Stock Information
| Ticker Symbol | AGN |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Unique Identifier | NYSE: AGN |
| IPO Date | February 17, 1993 |
Description
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; In addition, it develops medical and cosmetic treatments; treatments for neurodegenerative disorders; and inflammatory and fibrotic diseases. It has a collaboration, option, and license agreement with Lyndra, Inc. to develop orally administered products for the treatment of Alzheimer's disease; strategic alliance and option agreement with Editas Medicine, Inc.; and Allergan plc also has licensing agreements with Assembly Biosciences, Inc. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was incorporated in 2013 and is headquartered in Dublin, Ireland. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc.